|
1
|
Wirries A, Schubert AK, Zimmermann R,
Jabari S, Ruchholtz S and El-Najjar N: Thymoquinone accelerates
osteoblast differentiation and activates bone morphogenetic
protein-2 and ERK pathway. Int Immunopharmacol. 15:381–386. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Stupp R, Mason WP, van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al: Radiotherapy plus concomitant and adjuvant temozolomide
for glioblastoma. N Engl J Med. 352:987–996. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Johnell O and Kanis JA: An estimate of the
worldwide prevalence and disability associated with osteoporotic
fractures. Osteoporos Int. 17:1726–1733. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rodan GA and Martin TJ: Therapeutic
approaches to bone diseases. Science. 289:1508–1514. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Liu Y, Liu JP and Xia Y: Chinese herbal
medicines for treating osteoporosis. Cochrane Database Syst Rev:
CD005467. 2014.
|
|
6
|
Keung WM, Lazo O, Kunze L and Vallee BL:
Potentiation of the bioavailability of daidzin by an extract of
Radix puerariae. Proc Natl Acad Sci USA. 93:pp. 4284–4288. 1996;
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Maji AK, Pandit S, Banerji P and Banerjee
D: Pueraria tuberosa: A review on its phytochemical and therapeutic
potential. Nat Prod Res. 28:2111–2127. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Persson I, Weiderpass E, Bergkvist L,
Bergström R and Schairer C: Risks of breast and endometrial cancer
after estrogen and estrogen-progestin replacement. Cancer Causes
Control. 10:253–260. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Orija IB and Mehta A: Hormone replacement
therapy: Current controversies. Clin Endocrinol (Oxf). 59:6572003.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Carthew RW and Sontheimer EJ: Origins and
mechanisms of miRNAs and siRNAs. Cell. 136:642–655. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Erson AE and Petty EM: MicroRNAs in
development and disease. Clin Genet. 74:296–306. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Laneve P, Di Marcotullio L, Gioia U, Fiori
ME, Ferretti E, Gulino A, Bozzoni I and Caffarelli E: The interplay
between microRNAs and the neurotrophin receptor tropomyosin-related
kinase C controls proliferation of human neuroblastoma cells. Proc
Natl Acad Sci USA. 104:pp. 7957–7962. 2007; View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wang X, Tang S, Le SY, Lu R, Rader JS,
Meyers C and Zheng ZM: Aberrant expression of oncogenic and
tumor-suppressive microRNAs in cervical cancer is required for
cancer cell growth. PLoS One. 3:e25572008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Song G, Zhang Y and Wang L: MicroRNA-206
targets notch3, activates apoptosis, and inhibits tumor cell
migration and focus formation. J Biol Chem. 284:31921–31927. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Thompson BJ and Cohen SM: The Hippo
pathway regulates the bantam microRNA to control cell proliferation
and apoptosis in Drosophila. Cell. 126:767–774. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li X and Carthew RW: A microRNA mediates
EGF receptor signaling and promotes photoreceptor differentiation
in the Drosophila eye. Cell. 123:1267–1277. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Kawasaki H and Taira K: Retraction: Hes1
is a target of microRNA-23 during retinoic-acid-induced neuronal
differentiation of NT2 cells. Nature. 426:1002003. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Foekens JA, Sieuwerts AM, Smid M, Look MP,
de Weerd V, Boersma AW, Klijn JG, Wiemer EA and Martens JW: Four
miRNAs associated with aggressiveness of lymph node-negative,
estrogen receptor-positive human breast cancer. Proc Natl Acad Sci
USA. 105:pp. 13021–13026. 2008; View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Arfat Y, Xiao WZ, Ahmad M, Zhao F, Li DJ,
Sun YL, Hu L, Zhihao C, Zhang G, Iftikhar S, et al: Role of
microRNAs in osteoblasts differentiation and bone disorders. Curr
Med Chem. 22:748–758. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Papaioannou G, Mirzamohammadi F and
Kobayashi T: MicroRNAs involved in bone formation. Cell Mol Life
Sci. 71:4747–4761. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pi C, Li YP, Zhou X and Gao B: The
expression and function of microRNAs in bone homeostasis. Front
Biosci. 20:119–138. 2015. View
Article : Google Scholar
|
|
23
|
Wang T, Yin H, Wang J, Li Z, Wei H, Liu Z,
Wu Z, Yan W, Liu T, Song D, et al: MicroRNA-106b inhibits
osteoclastogenesis and osteolysis by targeting RANKL in giant cell
tumor of bone. Oncotarget. 6:18980–18996. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Horiguchi Y, Nakai T and Kume K: Effects
of Bordetella bronchiseptica dermonecrotic toxin on the structure
and function of osteoblastic clone MC3T3-e1 cells. Infect Immun.
59:1112–1116. 1991.PubMed/NCBI
|
|
25
|
James AW: Review of signaling pathways
governing MSC osteogenic and adipogenic differentiation.
Scientifica (Cairo). 2013:6847362013.PubMed/NCBI
|
|
26
|
Tang X, Lin J, Wang G and Lu J:
MicroRNA-433-3p promotes osteoblast differentiation through
targeting DKK1 expression. PLoS One. 12:e01798602017. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Wang Y, Yang C, Xie WL, Zhao YW, Li ZM,
Sun WJ and Li LZ: Puerarin concurrently stimulates osteoprotegerin
and inhibits receptor activator of NF-κB ligand (RANKL) and
interleukin-6 production in human osteoblastic MG-63 cells.
Phytomedicine. 21:1032–1036. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Lv H, Che T, Tang X, Liu L and Cheng J:
Puerarin enhances proliferation and osteoblastic differentiation of
human bone marrow stromal cells via a nitric oxide/cyclic guanosine
monophosphate signaling pathway. Mol Med Rep. 12:2283–2290. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Wang C, Meng MX, Tang XL, Chen KM, Zhang
L, Liu WN and Zhao YY: The proliferation, differentiation, and
mineralization effects of puerarin on osteoblasts in vitro. Chin J
Nat Med. 12:436–442. 2014.PubMed/NCBI
|
|
31
|
Wong R and Rabie B: Effect of puerarin on
bone formation. Osteoarthritis Cartilage. 15:894–899. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Urasopon N, Hamada Y, Cherdshewasart W and
Malaivijitnond S: Preventive effects of Pueraria mirifica on bone
loss in ovariectomized rats. Maturitas. 59:137–148. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Sheu SY, Tsai CC, Sun JS, Chen MH, Liu MH
and Sun MG: Stimulatory effect of puerarin on bone formation
through co-activation of nitric oxide and bone morphogenetic
protein-2/mitogen-activated protein kinases pathways in mice. Chin
Med J (Engl). 125:3646–3653. 2012.PubMed/NCBI
|
|
34
|
Li Z, Hassan MQ, Volinia S, van Wijnen AJ,
Stein JL, Croce CM, Lian JB and Stein GS: A microRNA signature for
a BMP2-induced osteoblast lineage commitment program. Proc Natl
Acad Sci USA. 105:pp. 13906–13911. 2008; View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kapinas K, Kessler C, Ricks T, Gronowicz G
and Delany AM: miR-29 modulates Wnt signaling in human osteoblasts
through a positive feedback loop. J Biol Chem. 285:25221–25231.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Itoh T, Nozawa Y and Akao Y: MicroRNA-141
and −200a are involved in bone morphogenetic protein-2-induced
mouse pre-osteoblast differentiation by targeting distal-less
homeobox 5. J Biol Chem. 284:19272–19279. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Shi K, Lu J, Zhao Y, Wang L, Li J, Qi B,
Li H and Ma C: MicroRNA-214 suppresses osteogenic differentiation
of C2C12 myoblast cells by targeting Osterix. Bone. 55:487–494.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Collison J: Bone: miR-106b promotes
osteoporosis in mice. Nat Rev Rheumatol. 13:1302017. View Article : Google Scholar
|
|
39
|
Liu K, Jing Y, Zhang W, Fu X, Zhao H, Zhou
X, Tao Y, Yang H, Zhang Y, Zen K, et al: Silencing miR-106b
accelerates osteogenesis of mesenchymal stem cells and rescues
against glucocorticoid-induced osteoporosis by targeting BMP2.
Bone. 97:130–138. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Chuang TD, Luo X, Panda H and Chegini N:
miR-93/106b and their host gene, MCM7, are differentially expressed
in leiomyomas and functionally target F3 and IL-8. Mol Endocrinol.
26:1028–1042. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Ni X, Xia T, Zhao Y, Zhou W, Wu N, Liu X,
Ding Q, Zha X, Sha J and Wang S: Downregulation of miR-106b induced
breast cancer cell invasion and motility in association with
overexpression of matrix metalloproteinase 2. Cancer Sci.
105:18–25. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Dong P, Kaneuchi M, Watari H, Sudo S and
Sakuragi N: MicroRNA-106b modulates epithelial-mesenchymal
transition by targeting TWIST1 in invasive endometrial cancer cell
lines. Mol Carcinog. 53:349–359. 2014. View
Article : Google Scholar : PubMed/NCBI
|
|
43
|
Zheng L, Zhang Y, Lin S, Sun A, Chen R and
Ding Y and Ding Y: Down-regualtion of miR-106b induces
epithelial-mesenchymal transition but suppresses metastatic
colonization by targeting Prrx1 in colorectal cancer. Int J Clin
Exp Pathol. 8:10534–10544. 2015.PubMed/NCBI
|
